Timothy Schacker

Executive Vice Dean (EVD)
Director, Program in HIV Medicine
Professor of Medicine, Division of Infectious Diseases and International Medicine


Administrator Info
Name: Craig Olson
Phone: 612-626-6577
Email: olso7966@umn.edu
Mail: 420 Delaware ST SE
MMC 250
Campus Delivery Code 8250A
Minneapolis, MN 55455

Timothy Schacker, M.D. is a professor of Medicine and Director of the Program in HIV Medicine at the University of Minnesota. He joined the faculty in 1996. Dr. Schacker received his M.D. from the University of Minnesota in 1986 and completed a residency in Internal Medicine at the Oregon Health Sciences University and Infectious Disease Fellowship at the University of Washington in 1993. He then joined the faculty of the University of Minnesota.Dr. Schacker is interested in how HIV causes immune suppression and why antiretrovirals do not fully restore immunity. His group focuses on inflammatory damage in lymphatic tissues; the principal site of HIV infection, that results in fibrosis of the lymphatic structures required to maintain a normal population of CD4 cells. They are testing novel therapies to prevent and/or reverse this process and slow T cell depletion in HIV and improve their reconstitution when antiretroviral is begun. He is also the principal investigator of a federally funded program of projects designed to determine barriers to HIV eradication. In addition, Dr. Schacker has established a collaboration with the Joint Clinical Research Center in Kampala, Uganda to study how constant exposure to common infections like tuberculosis, malaria, and helminthic infections affect rates of HIV transmission and progression.

Research Summary

IL-15 to Deplete HIV Reservoirs and Improve Immune Responses; Antifibrotic Therapy to Improve Immune Reconstitution in HIV

Research Funding Grants

  • Predictors of Time to Viremia with an Analytic Treatment Interruption, amfAR, 109496-60-RGRL, Principal Investigator.
  • Reservoir Dynamics in Patients Treated in Very Early Acute HIV Infection, NIH, R01 AI125127, Principal Investigator.
  • Reversing Tissue Fibrosis to Improve Immune Reconstruction in HIV, NIH, U01AI105872, Principal Investigator.
  • Antifibrotic Therapy to Improve Immune Reconstitution in HIV, NIH, R01 AI093319-01A1, Principal Investigator.
  • IL-15 to Deplete HIV Reservoirs and Improve Immune Responses, Altor Bioscience, ALT-803, Principal Investigator.

Clinical Summary



MD, University of Minnesota

Honors and Recognition

Top Doctors, Mpls.St.Paul Magazine
Best Doctors in America® (2011-2012, 2013)

Professional Memberships

American College of Physicians
Infectious Disease Society of America
International Society for Antiviral Research
American Federation for Clinical Research
American Society of Microbiology
International AIDS Society
Selected Publications

Selected Publications

Leong YA, Chen Y, Ong HS, Wu D, Man K, Deleage C, Minnich M, Meckiff BJ, Wei Y, Hou Z, Zotos D, Fenix KA, Atnerkar A, Preston S, Chipman JG, Beilman GJ, Allison CC, Sun L, Wang P, Xu J, Toe JG, Lu HK, Tao Y, Palendira U, Dent AL, Landay AL, Pellegrini M, Comerford I, McColl SR, Schacker TW, Long HM, Estes JD, Busslinger M, Belz GT, Lewin SR, Kallies A, Yu D.CXCR5(+) follicular cytotoxic T cells control viral infection in B cell follicles.Nat Immunol. 2016 Oct;17(10):1187-96. doi: 10.1038/ni.3543. Epub 2016 Aug 3.PMID: 27487330,
Lederman MM, Cannon PM, Currier JS, June CH, Kiem HP, Kuritzkes DR, Lewin SR, Margolis DM, McCune JM, Mellors JW, Schacker TW, Sekaly RP, Tebas P, Walker BD, Douek DC. A Cure for HIV Infection: "Not in My Lifetime" or "Just Around the Corner"? Pathog Immun. 2016 Spring;1(1):154-164. PMID: 27668293,
Estes JD, Kityo C, Ssali F, Swainson L, Makamdop KN, Del Prete GQ, Deeks SG, Luciw PA, Chipman JG, Beilman GJ, Hoskuldsson T, Khoruts A, Anderson J, Deleage C, Jasurda J, Schmidt TE, Hafertepe M, Callisto SP, Pearson H, Reimann T, Schuster J, Schoephoerster J, Southern P, Perkey K, Shang L, Wietgrefe SW, Fletcher CV, Lifson JD, Douek DC, McCune JM, Haase AT, Schacker TW. Defining total-body AIDS-virus burden with implications for curative strategies. Nat Med. 2017 Oct 2. doi: 10.1038/nm.4411. [Epub ahead of print] PMID:28967921,
Du J, Paz K, Flynn R, Vulic A, Robinson TM, Lineburg KE, Alexander KA, Meng J, Roy S, Panoskaltsis-Mortari A, Loschi M, Hill GR, Serody JS, Maillard I, Miklos D, Koreth J, Cutler CS, Antin JH, Ritz J, MacDonald KP, Schacker TW, Luznik L, Blazar BR. Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage and TGF-b production. Blood. 2017 Mar 2. pii: blood-2017-01-758854. doi: 10.1182/blood-2017-01-758854. [Epub ahead of print] PMID: 28254742,
Kityo C, Nganou-Makamdop K, Rothenberger M, Chipman JG, Hoskuldsson T, Beilman GJ, Grzywacz B, Mugyenyi P, Ssali F, Akondy RS, Anderson J, Schmidt T, Reimann T, Callisto S, Schoephoerster J, Schuster J, Muloma N, Ssengendo P, Moysi E, Petrovas C, Lanciotti R, Zhang L, Arevalo MT, Rodriguez B, Ross TM, Trautmann L, Sekaly R, Lederman MM, Koup R, Ahmed R, Reilly C, Douek DC, Schacker TW. Lymphoid tissue fibrosis is associated with impaired vaccine responses. J Clin Invest. 2018 May 21. pii: 97377. doi: 10.1172/JCI97377. [Epub ahead of print] PMID: 29781814,